Recombinant IL-3 in HIV seropositive patients with cytopenias: effective long-term therapy (Meeting abstract).

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Recombinant IL-3 in HIV seropositive patients with cytopenias: effective long-term therapy (Meeting abstract).

Proc Annu Meet Am Soc Clin Oncol; 15:A851 1996. Unique Identifier : AIDSLINE ICDB/97635851
Von Roenn JH; Gordon LI; Grace W; Lee S; Northwestern University, Chicago, IL

Abstract: HIV-infected patients develop multi-lineage bone marrow suppression which may compromise the ability to deliver optimal therapy for infections and neoplastic diseases. IL-3 is a multi-lineage hematopoietic-growth factor which has been shown in vitro to augment HIV expression in monocytes. We previously reported (ASCO; 1994) that rIL-3 (over 3 weeks) results in significant improvement in ANC and platelets for patients with HlV-related myelosuppression without toxicity or increases in viral proliferation. We have treated 12 HIV+ patients with rIL-3, and now report the long-term effects of treatment in the 8 patients who were treated for greater than 3 months. Patient characteristics: 2 women, 6 men, median age 38.7 years (range 23.5 to 48). All had ECOG performance status 0. Median CD4 count 60 cells/mm3 (range 10 to 220), median ANC at entry 895 (range 288 to 2016), median platelet count at entry 123,000 (range 21,000 to 220,000). Two patients were treated with rIL-3 1 ug/kg/day sq, 5 patients with rIL-3 2.5 ug/kg/day sq, and 1 with rIL-3 5.0 ug/kg/day sq. Median duration of rIL-3 therapy: 12 months (range 4.7 to 31.3). All 8 patients had hematologic efficacy (ANC greater than 2000 or doubling of ANC) without significant toxicity. Two had entry platelet counts less than or equal to 100,000/mm3, and both had doubling of platelet count or count greater than 100,000. All 8 patients maintained their ANC at greater than 500 (12% - 222% increase from baseline) without significant toxicity. Patients discontinued therapy for the following reasons: 1 patient developed an AIDS-related complication (20 months), 1 patient had a nondrug-related cardiac death (5.9 months), 4 patients voluntarily withdrew from study (4.7, 4.8, 10.6 and 13.7 months). Two patients were still on treatment at day 935. We conclude that rIL-3 is effective for the treatment of HIV-associated cytopenias and can be given for up to 3 years without significant toxicity.

Keywords: Adult CD4 Lymphocyte Count Female HIV Infections/*COMPLICATIONS Human Interleukin-3/*THERAPEUTIC USE Male Middle Age Neutropenia/COMPLICATIONS/*THERAPY Recombinant Proteins/THERAPEUTIC USE Thrombocytopenia/COMPLICATIONS/*THERAPY ABSTRACT
970330
M9731534

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .